Serum soluble CD163 predicts risk of type 2 diabetes in the general population.

BACKGROUND Activation of adipose tissue macrophages with concomitant low-grade inflammation is believed to play a central role in the development of type 2 diabetes. We tested whether a new macrophage-derived biomarker, soluble CD163 (sCD163), identifies at-risk individuals before overt disease has developed. METHODS A prospective cohort study of 8849 study participants from the general population, the Copenhagen City Heart Study, was followed for 18 years for incidence of type 2 diabetes. Risk of disease was calculated according to age- and sex-adjusted percentile categories of serum sCD163 concentrations: 0%-33%, 34%-66%, 67%-90%, 91%-95%, and 96%-100%. RESULTS A total of 568 participants developed type 2 diabetes. The cumulative incidence increased with increasing baseline sCD163 (trend P < 0.001), and sCD163 was strongly associated with known risk factors such as physical inactivity, body mass index, C-reactive protein, and triglycerides (all P < 0.001). Multifactorially adjusted hazard ratios for type 2 diabetes were 1.4 (95% CI, 1.0-1.9), 2.4 (1.8-3.2), 3.8 (2.6-5.5), and 5.2 (3.6-7.6) for categories 34%-66%, 67%-90%, 91%-95%, and 96%-100%, respectively, vs the 0%-33% category. In overweight men 50-70 and >70 years of age, serum sCD163 concentrations in the top 5% group predicted an absolute 10-year risk of type 2 diabetes of 29% and 36% vs 7% and 8% in the lowest percentile group. Equivalent values in women were 19% and 24% vs 4% and 5%. CONCLUSIONS Increased concentrations of sCD163 predict increased risk of type 2 diabetes in the general population and may be useful for identification of high-risk overweight individuals.

[1]  S. Moestrup,et al.  Soluble macrophage-derived CD163: a homogenous ectodomain protein with a dissociable haptoglobin-hemoglobin binding. , 2010, Immunobiology.

[2]  F. Rubino,et al.  The Diabetes Surgery Summit Consensus Conference: Recommendations for the Evaluation and Use of Gastrointestinal Surgery to Treat Type 2 Diabetes Mellitus , 2010, Annals of surgery.

[3]  E. Moler,et al.  Development of a Type 2 Diabetes Risk Model From a Panel of Serum Biomarkers From the Inter99 Cohort , 2010, Diabetes Care.

[4]  B. Ludvik,et al.  Diminished upregulation of visceral adipose heme oxygenase-1 correlates with waist to hip ratio and insulin resistance , 2010, International Journal of Obesity.

[5]  David M Nathan,et al.  10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. , 2009, Lancet.

[6]  K. Clément,et al.  Human adipose tissue macrophages: m1 and m2 cell surface markers in subcutaneous and omental depots and after weight loss. , 2009, The Journal of clinical endocrinology and metabolism.

[7]  C. Buechler,et al.  Adiponectin downregulates CD163 whose cellular and soluble forms are elevated in obesity , 2009, European journal of clinical investigation.

[8]  Torben Hansen,et al.  Development of a Type 2 Diabetes Risk Model From a Panel of Serum Biomarkers From the Inter99 Cohort , 2009, Diabetes Care.

[9]  S. Bojesen,et al.  Elevated plasma YKL-40 predicts increased risk of gastrointestinal cancer and decreased survival after any cancer diagnosis in the general population. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  R. Gupta,et al.  Consensus statement for diagnosis of obesity, abdominal obesity and the metabolic syndrome for Asian Indians and recommendations for physical activity, medical and surgical management. , 2009, The Journal of the Association of Physicians of India.

[11]  Børge G Nordestgaard,et al.  Association of loss-of-function mutations in the ABCA1 gene with high-density lipoprotein cholesterol levels and risk of ischemic heart disease. , 2008, JAMA.

[12]  B. Nordestgaard,et al.  Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population: the Copenhagen City Heart Study. , 2008, Circulation.

[13]  William M. Lee,et al.  Soluble CD163 from activated macrophages predicts mortality in acute liver failure. , 2007, Journal of hepatology.

[14]  T. Stulnig,et al.  Adipose tissue macrophages. , 2007, Immunology letters.

[15]  V. Fuster,et al.  Downregulation of the Hemoglobin Scavenger Receptor in Individuals With Diabetes and the Hp 2-2 Genotype: Implications for the Response to Intraplaque Hemorrhage and Plaque Vulnerability , 2007, Circulation research.

[16]  G. Zlabinger,et al.  Human adipose tissue macrophages are of an anti-inflammatory phenotype but capable of excessive pro-inflammatory mediator production , 2007, International Journal of Obesity.

[17]  P Zimmet,et al.  International Diabetes Federation: a consensus on Type 2 diabetes prevention , 2007, Diabetic medicine : a journal of the British Diabetic Association.

[18]  J. Després,et al.  Abdominal obesity and metabolic syndrome , 2006, Nature.

[19]  J. Carrero,et al.  Changes in fat mass correlate with changes in soluble sCD163, a marker of mature macrophages, in patients with CKD. , 2006, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[20]  S. Moestrup,et al.  Macrophage serum markers in pneumococcal bacteremia: Prediction of survival by soluble CD163* , 2006, Critical care medicine.

[21]  S. Vogel,et al.  Pivotal Advance: Activation of cell surface Toll‐like receptors causes shedding of the hemoglobin scavenger receptor CD163 , 2006, Journal of leukocyte biology.

[22]  S. Moestrup,et al.  The monocytic lineage specific soluble CD163 is a plasma marker of coronary atherosclerosis. , 2006, Atherosclerosis.

[23]  K. Wellen,et al.  Inflammation, stress, and diabetes. , 2005, The Journal of clinical investigation.

[24]  M. Kurrer,et al.  Soluble hemoglobin–haptoglobin scavenger receptor CD163 as a lineage‐specific marker in the reactive hemophagocytic syndrome , 2005, European journal of haematology.

[25]  K. Clément,et al.  The FASEB Journal • Research Communication Weight loss regulates inflammation-related genes in white adipose tissue of obese subjects , 2022 .

[26]  S. Wild,et al.  Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. , 2004, Diabetes care.

[27]  S. Moestrup,et al.  Plasma level of the macrophage‐derived soluble CD163 is increased and positively correlates with severity in Gaucher's disease , 2004, European journal of haematology.

[28]  S. Moestrup,et al.  CD163: a regulated hemoglobin scavenger receptor with a role in the anti‐inflammatory response , 2004, Annals of medicine.

[29]  M. Desai,et al.  Obesity is associated with macrophage accumulation in adipose tissue. , 2003, The Journal of clinical investigation.

[30]  L. Tartaglia,et al.  Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. , 2003, The Journal of clinical investigation.

[31]  R. Muniyappa,et al.  The diabetes prevention program , 2003, Current diabetes reports.

[32]  S. Moestrup,et al.  Characterization of an enzyme-linked immunosorbent assay for soluble CD163 , 2002, Scandinavian journal of clinical and laboratory investigation.

[33]  S. Moestrup,et al.  Identification of the hemoglobin scavenger receptor/CD163 as a natural soluble protein in plasma. , 2002, Blood.

[34]  S. Moestrup,et al.  Identification of the haemoglobin scavenger receptor , 2001, Nature.

[35]  S. Neubauer,et al.  Alterations in myocardial creatinine kinase (CK) and lactate dehydrogenase (LDH) isoenzyme‐distribution in a model of left ventricular dysfunction , 2001, European journal of heart failure.

[36]  P. Schnohr.  The Copenhagen City Heart Study : Østerbroundersøgelsen : tables with data from the third examination 1991-1994 , 2001 .

[37]  R. Collins,et al.  Underestimation of risk associations due to regression dilution in long-term follow-up of prospective studies. , 1999, American journal of epidemiology.

[38]  K. Uysal,et al.  Protection from obesity-induced insulin resistance in mice lacking TNF-α function , 1997, Nature.

[39]  K. Uysal,et al.  Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. , 1997, Nature.

[40]  B. Spiegelman,et al.  Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. , 1995, The Journal of clinical investigation.

[41]  B. Spiegelman,et al.  Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. , 1993, Science.

[42]  M. Feinglos,et al.  Stress and Diabetes , 1984 .

[43]  R. Levy,et al.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. , 1972, Clinical chemistry.